Genetic landscape of extreme responders with anaplastic oligodendroglioma.

ABSTRACT:

Background

The NRG Oncology RTOG 9402 trial showed significant survival benefit in patients with 1p/19q co-deleted anaplastic oligodendrogliomas (AO) who received both radiation (RT) and chemotherapy (PCV regimen) versus RT alone. Substantial separation of the survival curves was only seen after 7.3 years. We aimed to determine whether there are specific genetic alterations that distinguish co-deleted AO patients who benefit from the addition of PCV from those who do not.

Methods

We performed whole exome sequencing on matched tumor and normal DNA from all available short-term (STS) and long-term survivors (LTS) who received RT+PCV. hTERT status and rs55705857 genotypes (G-allele) were analyzed in both cohorts.

Results

Six STS (survival of <7.3y) and 7 LTS (survival of

SUBMITTER: Holdhoff M 

PROVIDER: S-EPMC5482595 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature